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Abstract
Introduction—The novel coronavirus (CoV) disease 2019 (COVID-19) is a viral infection that
causes Severe Acute Respiratory Syndrome. It is believed that early reports of COVID-19 cases
were noticed in December 2019 and soon after became a global public health emergency. It is
advised that COVID-19 transmits through human to human contact and in most cases it remains
asymptomatic. Several approaches are being utilized to control the outbreak of this fatal viral
disease. microRNAs (miRNAs) are known signature therapeutic tool for the viral diseases; they
are small non-coding RNAs that target the mRNAs to inhibit their post-transcriptional expression,
therefore, impeding their functions, thus can serve as watchdogs or micromanagers in the cells.

Author Manuscript

Areas covered—This review work delineated COVID-19 and its association with SARS-CoV
and MERS-CoV, the possible role of miRNAs in the pathogenesis of COVID-19, and therapeutic
potential of microRNAs and their effective delivery to treat COVID 19.
Expert opinion—This review highlighted the importance of various miRNAs and their potential
role in fighting with this pandemic as therapeutic molecules utilizing nanotechnology.
Keywords
SARS-CoV-2; COVID-19; miRNA; nanotherapeutics; nanoparticles

1.

Introduction

Author Manuscript

A novel Coronavirus Disease 2019 (COVID-19) belongs to Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) and has been discovered in humans for the first
time [1]. Coronavirus has been linked to a category of pathogens that impacts the respiratory
system of humans. According to World Health Organization (WHO), COVID-19 has
symptoms ranging from common cold to high fever, and to trouble in breathing. In severe
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infection conditions, COVID-19 can be an acute respiratory syndrome which leads to kidney
failure, and progresses to death [2–4]. Prior to SARS-CoV-2, two major known
coronaviruses, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle
East Respiratory Syndrome Coronavirus (MERS-CoV) were discovered [5]. COVID-19 has
been reported to emerge from Wuhan, Hubei, China, in the end of December 2019 when few
patients were admitted to the hospitals diagnosed with unexplained pneumonia and later this
spread was suspected to be associated with the wet market in Wuhan, China [6,7].

Author Manuscript

The SARS-CoV-2 belongs to the β-subfamily of coronaviruses similar to SARS-CoV and
MERS-CoV [8,9]. Among all other 7 types of coronaviruses, β subtype is the most fatal [8].
Coronaviruses were first identified by Tyrell and Bynoe in 1966 as positive single stranded,
enveloped RNA viruses with a genomic size of 26–32 kb, that can infect both mammals and
humans [10]. Through literature, it has been considered that SARS-CoV-2 consists of four
structural proteins (the spike, membrane, envelope, and nucleocapsid) and RNA viral
genome (Figure 1). The whole structure is about 60–140 nm in diameter. The structure of
SARS-CoV-2 is considered as a core-shell morphology.
Coronaviruses also replicate in the host cytoplasm, like other RNA viruses [11]. Recently,
published reports suggested that SARS-CoV-2 was originally transmitted from bats [12,13]
and the whole genome of human SARS-CoV-2 was found to be almost 96% identical to the
coronavirus of a bat [9]. Bats were reportedly acclaimed as the natural reservoir for other
coronaviruses, such as, SARS-CoV, MERS-CoV, HCoV-NL63, and HCoV-229E [14–16].

Author Manuscript

Most COVID-19 patients were reported to have some other underlying co-morbidity factors,
such as, diabetes, respiratory health condition, cardiovascular condition, hypertension, and
cancer [3]. According to many reports, the median age of COVID-19 confirmed cases/
patients was around 60 years and older, and more than half the population was male. The
average incubation time for the virus is ~ 5 days [3,17].
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The most favorable route attributing to the transmission of this SARS-CoV-2 virus spread is
human to human contact [18,19] (Figure 2A). Upon the transmission, viral particles bind to
the host cell receptor and then get fused with the cell membrane. Being a respiratory
infection, primarily, SARS-CoV-2 was evident to target the airway and lung epithelial cells.
Growing evidences argue that receptor binding domain of SARS-CoV-2 spike protein gets
activated after its cleavage by Transmembrane Serine Protease 2 (TMPRSS2) and binds to
the Angiotensin Converting Enzyme 2 (ACE2) receptor of the host cells (Figure 2A) [20–
22]. Therefore, we hypothesized that identification and successful delivery of certain
microRNAs that are involved in blocking the binding or activation with ACE2 or TMPRSS2
is highly rewarding for the prevention and management of COVID-19 (Figure 2B). More
detailed information on these aspects are provided in the forthcoming sections.

2.

Association with SARS-CoV and MERS-CoV
COVID-19 has many similarities with the previous two viral infections of its family. Both
SARS-CoV and SARS-CoV-2 viruses have originated in China and been linked with animal
markets. COVID-19 and MERS both are reported to be asymptomatic in large number of
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cases [23]. Nonetheless, COVID-19 has also been documented as a contagious and
respiratory disease which is another similarity with SARS and MERS [4]. Transmission of
all three global health threats has also been via similar means as human to human contacts
and, through cough and sneeze droplets in the air [24,25].

Author Manuscript

Moreover, the receptor binding domain sequence of SARS-CoV-2 is similar to that of
SARS-CoV [11]. SARS was a global epidemic exploded in 2003 [26] whereas MERS was
the second known coronavirus pandemic and was first reported in 2012 in Saudi Arabia [26].
Reports claimed that these viruses have emerged from bats and camels and transmitted to
humans [27,28]. Spread of both viral diseases (SARS and MERS) was worldwide as early
clinical features were not clear. MERS was less severe compared to SARS as it did not show
global transmission quickly, not even after two years of its first emergence. Previous
measures taken to combat SARS and MERS should be reconsidered to better tackle this
newer global pandemic, including, maintaining social distancing, proper hygiene, selfquarantine (if any symptoms are present), and isolation (of confirmed positive individuals)
[4].

3.

miRNAs in SARS, MERS and COVID-19 viral diseases
microRNAs (miRNAs) are about 18–25 nucleotides long, small non-coding RNAs that
regulate the target mRNAs post-transcriptionally, thus, serve as watchdogs in the cells
[29,30]. In the past recent years, many reports have identified miRNAs as signature
biomarkers that play a critical role in various cellular processes, such as, cell proliferation,
apoptosis, differentiation, and embryonic development [31]. Dysregulation in the expression
status of miRNAs has been associated with several diseases including viral diseases, cancer
[31,32], diabetes, schizophrenia [33,34], psoriasis [35], and cardiovascular disease [36].

Author Manuscript
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Growing evidences have suggested a vital role of miRNAs in the pathogenesis and
therapeutics of many viral diseases (Table 1), such as Dengue, Influenza, Human
Immunodeficiency Virus 1 (HIV-1), Herpes Simplex Viruses (HSV), and Hepatitis C
(HCV).A study has reported that miRNA 122 possesses strong anti-HCV characteristics
[37]. Based on a bioinformatics study, a group 13 cellular human miRNAs regulate the
MERS-CoV. Out of these, only 3 human miRNAs, miRNA 628–5p, miRNA 18a-3p, and
miRNA 332–3p have the known biological functions. Remaining 10 human miRNAs
(miRNA 6804–3p, miRNA 4289, miRNA 208a-3p, miRNA 510–3p, miRNA 329– 3p,
miRNA 548ax, miRNA 3934–5p, miRNA 4474–5p, miRNA 7974, and miRNA 6865–5p)
did not have any known role/functions in humans or animals. miRNA 628 and miRNA 332
exhibited remarkable identity with the MERS-CoV viral genome. As of the previously
known functions, miRNA 628 has been reported to play tumor suppressive role in
glioblastoma where it is crucial for cell proliferation and cell cycle progression [38]. miRNA
18a was also found to critically regulate the genes involved in cellular proliferation,
adhesion, and differentiation [39]. On the other hand, miRNA 332 was suggested to be
overexpressed in prion disease and crucial for late stage of the disease [40]. Considering the
resemblance between MERS and COVID-19, these miRNAs could also be potential targets
for COVID-19 therapeutics.
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Studies even suggested that some plant miRNAs are also identical with human miRNAs as
they share similar genomic sequences [52]. One plant-based miRNA, pab-miRNA 11409d
found in gymnosperm Picea abies (L), showed sequence similarity with 3’ of SARS-CoV-2
spike gene (NCBI Accession number LC528233.1), suggesting that it may be implemented
to cure the COVID-19 [53]. Anti-viral miRNAs present in the host cells are also of great
significance as they act as a crucial regulator of immune response via targeting viral gene
replication and expression during the viral infections. A geographical (USA, Wuhan, Italy,
India and Nepal) genomic study on COVID-19 reported 6 anti-viral host cell miRNAs
specific to SARS-CoV-2 such as hsa-let 7a (targets Non Structural Protein), hsa-miRNA 101
(targets Non Structural Protein), hsa-miRNA 126 (targets Nucleocapsid), hsa-miRNA 23b
(targets Spike protein), hsa-miRNA 378 (targets Nucleocapsid), and hsa-miRNA 98 (targets
Spike protein) [54].
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Patients suffering with diabetic and cardiac diseases who are on ACE2 enhancement drugs
(inhibitors and blockers that increase the expression of ACE2 receptor), are more prone to be
infected with SARS-CoV-2 [55], and ACE2 was found to be regulated by hsa-miRNA 27b
[54,56], therefore, these findings further notify of an important correlation between hsamiRNA 27b and SARS-CoV-2. It is also important to note that miRNA 27b is associated
with Indian origin variant genome of SARS-CoV-2 [54]. Viral protein replication/synthesis
occurs in the host cell and miRNAs inhibit the target mRNA translation into the protein,
therefore, miRNAs can be utilized as a therapeutic tool for viral diseases [57–59].
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Considering the importance of miRNAs, it becomes imperative to identify the miRNAs
regulating the pathogenesis of COVID-19 and/or other coronavirus diseases. Another
method to control COVID-19 and/or other two coronavirus diseases is, to utilize completely
complementary miRNAs (cc miRNA) that can target the viral gene and inhibit its posttranscriptional expression. The cc miRNAs (modified to 25–27 nucleotides), namely,
ID02510.3p-miRNA, ID00448.3p-miRNA, miRNA 3154, miRNA 7114–5p, miRNA 5197–
3p, ID02750.3p-miRNA, and ID01851.5p-miRNA showed a strong binding with the SARSCoV-2 viral genome, suggestively [60].

Author Manuscript

The izMiR (miRNA prediction software) and PANTHER, bioinformatics based
classification systems, identified the possible mature viral and host cell miRNA candidates
that could play a crucial role in SARS-CoV-2 infection [61]. According to this study, SARSCoV-2 genes (Spike, Envelope, Membrane, Nucleocapsid, ORF1ab, ORF3a, ORF6, ORF8,
ORF7a and ORF10) were targeted by multiple human miRNAs (Figure 3) and these
miRNAs already have previously known roles in multiple viral diseases, to illustrate,
ORF1ab and ORF3a, two SARS-CoV-2 viral genes, were shown to be targeted by hsamiRNA 203b-3p which was reported to suppress viral replication in Influenza [62].
According to a bioinformatics based study, the spike protein of the virus was shown to be
targeted by 67 different human miRNAs whereas this computational prediction indicated
that ORF1ab gene was targeted by 369 miRNAs [61]. On the other hand, 18 SARS-CoV-2
viral miRNAs were also identified in this study with their possible host cell target genes.
Majority of these target genes were transcription factors and mediators of RNA polymerase
II, mainly TAF 4, TAF 5, TAF 7L, SOX 11, TCF 4, TFDP 2, TRPS 1, BRF 1 and MED 1,
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MED 9, MED 12L, MED 19, respectively. Some signal transducers such as STAT 1 and
STAT 5B were also reported among the predicted target genes of viral miRNAs.
CHAC1 and RAD9A are two crucial proteins for apoptosis [63] and found to be targeted by
two SARS-CoV-2 viral miRNAs, namely as, miRNA MD2–5p and miRNA 147–3p [64]. In
addition, miRNA 66–3p was identified to target the transcription enhancer of TNF-α, a very
well-known cytokine [64]. TMPRSS2 has been linked to activate the spike protein of SARSCoV-2, therefore, promotes the infection [22]. This activator gene had been predicted to be
targeted by miRNA 147–3p in the gut. This study further identified two more viral miRNAs
as miRNA 198–3p and miRNA 359–5p that target and enhance the activity of Adenosine
Deaminases Acting on RNA (ADAR) and non-muscle myosin heavy chain 9 (MYH9),
respectively [64].

Author Manuscript

A PubMed search with the keywords “miRNA and SARS-CoV-2” (https://
pubmed.ncbi.nlm.nih.gov/?term=miRNA+and+SARS-CoV-2) indicated about 20 peerreviewed studies (data accessed on August 3, 2020). Out of these, we discussed the articles
which are highly important and provide a new direction to the field of miRNAs in
COVID-19 research. Guterres et al., [65] screened 60 SARS-CoV-2 genomes for the
possible identification of seed sponges which may be involved in binding with the human
miRNA, thus, preventing the interaction with their native targets. This study extracted a
perfect match with 11 nucleotides encompassing the seed region. Additionally, this study
demonstrated that there are 34 and 45 miRNAs for positive-sense and negative-sense viral
RNA, respectively, that can strongly bind to certain key SARS-CoV-2 genes. Through the
Kyoto Encyclopedia of Genes and Genomes pathway analysis prediction study [66], 7
important miRNAs (miRNAs 8066, 5197, 3611, 3934–3p, 1307–3p, 3691–3p and 1468–5p)
were identified that are perfectly linked with host responses and virus pathogenicity.
Another study of a sequence analysis of SARS-CoV-2 genome has identified that out of 10,
3 targets have been lost. This includes miR-197–5p [67].

Author Manuscript

Considering the significance of ACE2 and TMPRSS2 in SARS-CoV-2 infection, we also
performed a TargetScan (http://www.targetscan.org/vert_72/) search for the miRNAs that
could target these two receptors, and the analyses revealed a list of miRNAs such as, hsamiRNA 200b-3p, hsa-miRNA 200c-3p and miRNA 429 for ACE2, and hsa-let 7c-5p, hsamiRNA 98–5p, hsa-let 7f-5p, hsa-let 7a-5p, hsa-let 7g-5p, hsa-let 7b-5p, hsa-miRNA 4458,
hsa-let 7e-5p, hsa-let 7i-5p, hsa-let 7d-5p and hsa-miRNA 4500 for TMPRSS2. According
to this search result, these miRNAs appear to directly target ACE2 and TMPRSS2, hence,
could be utilized as potent therapeutic molecules to regulate key proteins that are required
for viral contraction and its entry to the host airway/lung epithelial cells.

Author Manuscript

4.

Therapeutic potential of miRNAs for COVID-19
Viruses cannot replicate on their own, thus, they utilize the host cell environment for their
replication. One of the many strategies that viruses use, is modifying the host cell miRNA
for their favor [49]. SARS-CoV viral infection in Bronchioalveolar Stem Cells (BASCs) was
reported to modulate the differentiation of BASCs for its successful replication as it cannot
replicate in the well differentiated cells [43]. In the host cell, SARS-CoV modulated the
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expression of various miRNAs such as miRNA 17, miRNA 574, miRNA 214, and moreover
the spike and nucleocapsid proteins of this virus inhibited the expression of miRNA 98 and
miRNA 223, respectively, to control the cellular differentiation in BASCs [43].

Author Manuscript

On the other hand, some host cell miRNAs modulate the target viral gene expression in the
immune response as to defend the cells [68]. Signifying to the relationship between miRNAs
and viral infection, miRNAs appear to be potential biomarkers and therapeutic targets in
viral diseases. Trobaugh and Klimstra [69] have delineated the various aspects of the
interaction between RNA viruses and cellular miRNAs, including factors influencing
miRNA-RNA virus interaction, miRNA interactions with the RNA viral genome, miRNAmediated stabilization of RNA virus genomes, modulation of host miRNA levels during viral
infections, miRNA-mediated changes in protein expression that alter host responses in
infection and promote viral replication, and maintenance of miRNA-binding sites in the
RNA virus genome. This review discusses, how “miRNAs can affect RNA virus replication
and pathogenesis through direct binding to the RNA virus genome or through virusmediated changes in the host transcriptome”. Additionally, this study documents the direct
and indirect interactions between cellular miRNAs and RNA viruses.

Author Manuscript

Currently, in the lack of COVID-19 treatments and vaccines which will take time to be
developed, it is important to note that discovering miRNA-based therapies can be an
attractive option for controlling the replication of the virus. Host cell miRNAs that were
predicted to target SARS-CoV-2 viral genes, warrant further research in cell lines and animal
models. ACE2 and TMPRSS2 are two important receptors that were reported to facilitate the
activation and binding of SARS-CoV-2, and its entry to the host cell. miRNAs that are
associated with these two receptors could act as a therapeutic modality for this virus. To
illustrate, host miRNA 27b regulates ACE2 and viral miRNA 147–3p targets TMPRSS2, if
these therapeutic miRNAs can be delivered to the cells, attachment of SARS-CoV-2 spike
protein and these receptors can be inhibited, therefore, contraction of viral infection can be
mitigated or minimized (Figure 2B). Additionally, miRNAs from our TargetScan search
seem to be directly targeting these two genes, herein, enhanced or restored expression of the
listed miRNAs in the host cell could suppress the expression/presence of ACE2 and
TMPRSS2, which will result in the inhibition of SARS-CoV-2 viral entry and infection in
the host cell.

Author Manuscript

In the field of medicine, miRNAs have been considered as promising biomarker(s) and novel
target(s) for therapeutic approaches. miRNAs as therapeutics [70] have extensively been
reviewed and documented for their key roles and recent advances in cancer and other
diseases (pulmonary and cardiac disorders, asthma, pneumonia, cardiac fibrosis, and so on).
However, in virology, the landscape of miRNAs as diagnostic and interventional medicine is
still an unexplored area of research. The major issues with miRNA based viral research/
therapy are, the delivery of miRNAs to the target cells/tissues, poor circulation/half-life (as
miRNAs are highly unstable), and the toxicity associated with conventional delivery
vehicles. Simple chemical modification can serve as a medium to improve stability of
miRNAs, but it may not provide in vivo and clinical translation. On the other hand, various
viral vectors (adenoviral, retroviral, and lentiviral vectors) have been widely applied to the
preclinical and clinical purposes. However, their poor miRNA loading efficacy, off-target
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toxicity, and immunogenicity significantly hamper their use. Thus, the development of nonviral delivery vectors is considered to be a suitable option for effective delivery of
microRNAs [71].
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Nanoparticle based delivery has been reported to tackle these above-mentioned obstacles
related to miRNA therapeutics [72,73]. Nanotherapeutics are one of the most favorable
platforms to effectively deliver the miRNAs to the host cells pertaining to their tiny size and
low molecular weight. Various nanoparticle carriers have been suggested for the successful
miRNA delivery mainly inorganic nanoparticles, polymeric particles, lipid nanoparticles and
others [74]. Among all these non-viral delivery systems, lipid-based carriers (complexed or
encapsulated miRNAs inside the lipoplex/liposome membrane-like surface) are the widely
employed category. Currently, this type of formulations (lipofectamine, SiPORT, and
DharmaFECT) [71,75] are already being used for in vitro and in vivo applications. On the
other hand, polymer-based delivery systems, such as PEI, PLGA, or other biodegradable
polymers-based carriers not only offer biocompatibility but also minimal toxicity and
efficient delivery. Nanoparticle cores protect the naked miRNA from its degradation, thus,
provide the enhanced circulation in the system. Also, due to the nanometer size range of
nanocarriers, targeted delivery of miRNAs is achieved [76]. Our lab has the expertise in
generating nanoformulations as we have successfully developed several miRNA-based
nanotherapeutics in the past (Figure 4) [77,78]. A relatively new concept of using exosomes
or endosomal vesicles (extracellular vesicles) as delivery vehicles, is also another option to
successfully deliver miRNAs [79]. Hence, utilization of miRNA with nanoparticles-based
delivery, has the great potential of becoming a novel therapeutic approach to tackle
COVID-19 pandemic.
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5.

Concluding remarks
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World Health Organization has declared the COVID-19, a global pandemic in February
2020, which has caused more than 4 million confirmed positive cases and more than quarter
million deaths globally as of May 8, 2020. COVID-19 has been reported in humans for the
first time, therefore, development of effective therapies is an unmet clinical need. Many
research groups have been focusing on understanding the genomic profile of the virus and
utilizing the repurposed drugs to treat COVID-19. A very few reports, so far, have reported
the miRNAs as therapeutic molecules for this disease. miRNAs control the posttranscriptional expression of target mRNA genes, therefore, have reported to play an
important role in the pathogenesis of many viral diseases including SARS-CoV and MERSCoV infections. In this review, we have shed the light on various important and previously
reported miRNAs in coronavirus diseases and, also how they can be beneficial for
combating this invisible enemy to protect the human race. This should be an active area for
future research to conduct detailed in vitro and in vivo experimental procedures for the
clinical translation of miRNAs into COVID-19 therapeutics.

6.

Expert opinion
Since the first emergence of SARS-CoV-2 in the later part of December 2019, more than
18.2 million people have been impacted globally with this viral infection. As of now, there is
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no FDA approved treatment modality available but to slow-down the spread of the pandemic
and control the number of infected people, some agencies allowed repurposing of few drugs
including hydroxychloroquine, chloroquine, remedesivir, and other HIV drugs under
Emergency Use Authorization (EUA). Along with these, many other treatments are under
investigation ranging from anti-viral drugs to plasma therapy and antibody drugs. As the
preventative measures, many vaccine candidates are also being tested (13 under clinical
trials and more than 100 in preclinical studies) (clinicaltrials.gov). In order to propose an
adequately feasible treatment option for SARS-CoV-2, researchers should focus on
understanding the components involving in the pathogenesis of the viral disease.
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miRNAs have emerged as newer group of components playing a crucial role in the
pathogenesis of many diseases including viral diseases with clinically relevant therapeutic
applications. In this review, we have highlighted several miRNAs that have identified for
SARS-CoV-2 using bioinformatic studies. These miRNAs are, however, subjected to further
in vitro and in vivo research, but still provide essential information on their possible role in
SARS-CoV-2 infection. As miRNAs regulate the expression of target genes (mRNA),
changing the expression status of miRNAs by overexpressing or knocking them down, can
result in desired therapeutic outcomes. Viral diseases can have dual functionality of miRNAs
as there could be viral miRNAs and host cell miRNAs. Host cell miRNAs could either
inhibit the viral genome or enhance the viral genome replication upon the interaction.
Despite having these advantages of miRNA therapeutics, delivery of naked miRNAs is often
associated with rapid degradation and non-specific target effects which can be overcome by
nanotechnology-based approach.
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The overall idea of developing nanoformulations of the SARS-CoV-2 related miRNAs is to
deliver these miRNAs successfully and safely to the cells to exert their therapeutic effects.
This review has proposed multifaceted targeting approach for SARS-CoV-2 utilizing
miRNA nanotherapy. Activation of SARS-CoV-2 spike protein upon the cleavage by
TMPRSS2 is the first event of viral infection which further leads the cleaved spike protein to
get fused with ACE2 membrane receptor of the host cells. Therefore, miRNAs that are
specific to activation and binding of spike protein are of great therapeutic potential. Like
other delivery systems, identification of suitable miRNA nanoformulations with
predetermined loading efficacy, sustained release, and targeting characteristics, is highly
warranted. In addition, miRNAs that could inhibit the viral replication in the host cell, could
also be enveloped in the nanoparticles to suppress the viral load.

Author Manuscript

Other than therapeutic purpose, nanoparticles-based miRNAs could also be used in the form
of nano-vaccines for the prevention from SARS-CoV-2. Nano-vaccines have several benefits
over traditional vaccines as they are specific for infection site and have minimal to no offtarget effects. Additionally, nano-vaccines can be developed as nasal spray/drops. In case of
SARS-CoV-2 infection, nasal spray nano-vaccine appears to be a more reliable modality as
it can directly activate the immune response in the respiratory tract including nasal passage
as well as the lungs which are the primary contraction sites for SARS-CoV-2 viral infection,
this also indicates the direct and specific delivery of miRNAs in the targeted sites. It is
important to develop a unique and multi-disciplinary team of pharmaceutical and
nanomedicine experts, and basic and clinical scientists, for the effective clinical translation
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of miRNA nanoformulations. However, applying already existing nanomedicine technology
has also revived the interest for effective implementation of miRNA delivery for COVID-19.
Oral delivery of therapeutics is always an easy step towards developing the medicines [71].
In the case of oral delivery of miRNAs, miRNA availability is highly challenging due to the
nucleic acid degradation in gastric environment. Therefore, developing formulations that are
suitable and can be applied to oral delivery of miRNAs is highly sought. Literature has
identified that chitosan [80], mannose modified chitosan [81], bovine milk derived exosomes
[82], bovine lactoferrin [83], lipidic [84], and PLGA-based nanoformulations [85] are
employed for effective oral delivery of miRNAs/ therapeutics. Hence, developing oral
nanoformulation(s) of miRNAs is achievable and is highly recommended for its successful
implementation into the clinic.
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•

The novel coronavirus disease 2019 (COVID-19) is caused due to SARSCoV-2 infection which has been declared a pandemic.

•

The importance of miRNAs in the pathogenesis of this viral disease is
summarized.

•

Currently, there is no approved treatment or vaccine for COVID-19 and
miRNAs can become a potential therapeutic tool.

•

This work delineates the overall idea of developing nanoformulation(s) of the
SARS-CoV-2 related miRNAs.

•

Multifaceted targeting approaches are required for miRNA nanotherapy for
effectively tackling SARS-CoV-2.

•

The nanoparticles-based miRNAs could also be used in the form of nanovaccines for the prevention from SARS-CoV-2.
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Figure 1.

Ultra-structure and morphological representation of SARS-CoV-2. The representation is for
visualization purpose only and not exact for scale and comparison.

Author Manuscript
Author Manuscript
Expert Rev Anti Infect Ther. Author manuscript; available in PMC 2022 February 01.

Chauhan et al.

Page 16

Author Manuscript
Author Manuscript
Author Manuscript

Figure 2.

Schematic representation of SARS-CoV-2 viral infection and inhibition of its binding,
activation, and replication using microRNAs. A. Binding and Fusion of SARS-CoV-2 into
the host cell. TMPRSS2 cleaves and activates the spike protein of SARS-CoV-2 which leads
the viral spike protein to bind to the host cell membrane receptor ACE2 and get fused into
the cell where it replicates and enhances the infection. B. Utilizing miRNA
nanotherapeutics, three viral windows can be targeted to inhibit the infection.
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Figure 3.

A comprehensive list of host cell miRNAs that target different SARS-CoV-2 proteins.
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Figure 4.

A schematic representation of different nanosystems that could be utilized for successful
miRNA nanotherapy.

Author Manuscript
Author Manuscript
Expert Rev Anti Infect Ther. Author manuscript; available in PMC 2022 February 01.

Chauhan et al.

Page 19

Table 1:

Author Manuscript

Role of different miRNAs in viral diseases.
Virus

miRNA

Function

Reference

James Canyon Virus (JCV)

miRNA J1 (Viral)

Downregulates early gene expression

[41]

Human Papilomavirus (HPV)

miRNA 203 (Cellular)

Downregulates expression of p63

[42]

SARS

miRNA 17
miRNA 214 (Cellular)

Facilitates gene replication
Helps in immune invasion

[43]

Herpes Simplex Virus (HSV)

miRNA LAT (Viral)

Anti-apoptotic role

[44]

Author Manuscript

Hepatitis C Virus (HCV)

miRNA 122 (Cellular)

Enhances viral replication

[45]

Human Immunodeficiency Virus (HIV)

miRNA N367 (Viral)

Reduces LTR transcription

[46]

Human Cytomegalovirus (HCMV)

miRNA UL23 (Viral)

Immunomodulation

[47]

Simian Virus 40 (SV 40)

miRNA S1 (Viral)

Downregulates early gene expression

[48]

Influenza

miRNA 507 (Cellular)

Helps adapting influenza AI (Avian Influenza) to mammalian
cells/species via targeting PB2

[49]

BK Virus (BKV)

miRNA B1 (Viral)

Downregulates early gene expression

[50]

Similarly, many studies have been conducted with SARS regarding its association with miRNAs. Qin et al., have utilized miRNA (Small noncoding RNA) based therapy to reduce the spike gene of SARS-CoV [51]. This strategy can also be utilized for SARS-CoV-2 inhibition as the spike
protein of this virus is involved in the binding and fusion to the host cells.
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